Top Markets
#1 Verus Coin Verus Coin +45.28%
#2 Status Status +19.17%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.58%
#4 GoPlus Security GoPlus Security +16.92%
#5 Wrapped NXM Wrapped NXM +15.51%
#6 Ontology Gas Ontology Gas +11.14%
#7 DMT-NAT DMT-NAT +9.14%
#8 BankrCoin BankrCoin +8.23%
#9 Pons Pons +7.43%
#10 Nesa Nesa +7.39%
Coin of the day
Verus Coin Verus Coin
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Curanex Pharmaceuticals Inc Common Stock Curanex Pharmaceuticals Inc Common Stock

Curanex Pharmaceuticals Inc Common Stock

CURX
Rang in aandelen #34063
Curanex Pharmaceuticals Inc. is an emerging biopharmaceutical company focused... Curanex Pharmaceuticals Inc. is an emerging biopharmaceutical company focused on identifying, advancing, and bringing to market plant-based medicines to address various inflammatory conditions. Their primary drug candidate, Phyto-N, is currently in development for a broad spectrum of health issues, including but not limited to ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne. Established in 1996 and based in Jericho, New York, the company was formerly known as Fordman Pharma Inc. before adopting its current name in November 2023.
Aandeelprijs
$0.223
Laatst gesynchroniseerd: 2026-08-14
Marktkapitalisatie
$6.32M
Verandering (1 dag)
1.64%
Verandering (1 jaar)
-
Land
US
Handel Curanex Pharmaceuticals Inc Common Stock (CURX)

Categorie

Healthcare
Winst voor Curanex Pharmaceuticals Inc Common Stock (CURX)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Curanex Pharmaceuticals Inc Common Stock bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Curanex Pharmaceuticals Inc Common Stock van 2026 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE